

Docket No.: 58070-CPA/RCE (47126) (PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Gregor Cevc

Application No.: 09/284,683 - Conf. No.: 2670 Art Unit: 1615

Filed: June 24, 1999 Examiner: G. S. Kishore

For: PREPARATION FOR THE TRANSPORT OF AN ACTIVE SUBSTANCE

**ACROSS BARRIERS** 

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the United States Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 58070 (47126). A duplicate copy of this paper is enclosed.

Dated: August 12, 2005

Respectfully submitted,

By Lisa Swiszcz Hazzard Registration No.: 44,368

EDWARDS & ANGELL LLE

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE uction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO Application Number 09/284,683-Conf. #2670 INFORMATION DISCLOSURE Filing Date June 24, 1999 STATEMENT BY APPLICANT First Named Inventor **Gregor Cevc** Art Unit 1615 (Use as many sheets as necessary) G. S. Kishore Examiner Name Sheet 1 of 1 58070-CPA/RCE (47126) Attorney Docket Number

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

		FORE	IGN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	T <sup>6</sup>
		EP-0 582 239		RHONE-POULENC RORER GMBH	Figures Appear	H
	ВВ	WO-95/35095	12-28-1995	YESSUM RESEARCH DEVELOPMENT COMPANY		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English tanguage Translation is attached.

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>				
	CA	Merck & Co., Inc., "The Merck Index, Tenth Edition," 1983.					
	СВ	Product information, "Tween 80 pure."					
	СС	Product information, "Polysorbate 80 VG."					
	CD	M. Foldvari, et al., "Dermal drug delivery by liposome encapsulation: Clinical and electron microscopic studies," <i>J. Microencapsulation</i> , Vol. 7, No. 4, pp. 479-489 (1990).					

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Caraidanad	
Cidilatore	Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.